NewAmsterdam Pharma N.V. (NAMS)

AI Score

Unlock

17.35

-0.12 (-0.69%)

At close: Apr 25, 2025, 12:45 PM

NewAmsterdam Pharma Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	12.77M	29.11M	2.13M	1.3M	1.59M	1.88M	1.57M	7.96M	1.38M	5.62M	46.75M	46.75M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	17.74K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	12.77M	29.11M	2.11M	1.3M	1.59M	1.88M	1.57M	7.96M	1.38M	5.62M	46.75M	46.75M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-43.23M	-24.36M	-49.08M	-51.42M	-44.3M	-47.97M	-38.93M	-36.74M	-30.43M	-28.64M	26.81M	26.81M	-10.85M	-9.94M	-4.98M	-4.98M	-104.33K	-1.36M	-1.36M	-1.36M
Interest Income	4.49M	4.44M	4.55M	2.86M	2.52M	2.75M	4.23M	869.35K	n/a	58.88K	87.5K	87.5K	189.24K	35K	68.5K	68.5K	n/a	n/a	n/a	n/a
Pretax Income	-92.18M	-16.65M	-36.41M	-86.89M	-42.53M	-46.07M	-35.09M	-38.74M	-40.45M	-38.82M	27.26M	27.26M	-17.69M	-9.56M	-4.74M	-4.74M	33.88K	-1.44M	-1.44M	-1.44M
Net Income	-92.18M	-16.65M	-36.41M	-86.89M	-42.54M	-46.09M	-35.09M	-38.74M	-40.45M	-38.82M	27.26M	27.26M	-17.69M	-9.56M	-4.74M	-4.74M	33.88K	-1.44M	-1.44M	-1.44M
Selling & General & Admin	24.31M	17.28M	15.38M	13.39M	10.17M	10.92M	9.03M	7.43M	4.79M	5.3M	4.65M	4.65M	2.17M	1.7M	700.5K	700.5K	104.33K	348.5K	348.5K	348.5K
Research & Development	34.9M	35.7M	35.83M	39.32M	35.72M	38.92M	31.47M	37.26M	27.03M	28.96M	15.29M	15.29M	8.68M	8.24M	4.28M	4.28M	1.01M	1.01M	1.01M	1.01M
Other Expenses	-3.21M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-2.72M	-2.72M	-2.72M	-2.72M
Operating Expenses	56M	54.11M	43.09M	91.05M	46.64M	50.7M	40.89M	47.56M	31.81M	44.38M	19.41M	19.41M	17.5M	9.52M	4.67M	4.67M	104.33K	-1.36M	-1.36M	-1.36M
Interest Expense	-3.21M	1.14M	853.14K	667.02K	1.73M	962.78K	3.1M	1.15M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	86K	86K	86K	86K
Selling & Marketing Expenses	-11.14M	3.55M	3.29M	n/a	1.64M	1.72M	429.79K	n/a	523.73K	562.3K	309.5K	309.5K	419.24K	405.5K	17K	17K	2.75K	2.75K	2.75K	2.75K
Cost & Expenses	56M	53.48M	43.09M	91.05M	46.64M	50.7M	40.89M	47.56M	31.81M	44.38M	19.41M	19.41M	17.5M	9.52M	4.67M	4.67M	104.33K	1.36M	1.36M	1.36M
Income Tax Expense	n/a	-1K	n/a	n/a	12.23K	12.77K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	6K	6K	6K	6K
Shares Outstanding (Basic)	94.36M	94.75M	94.71M	82.16M	82.48M	82.48M	81.85M	81.63M	1.67M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	86.13M	86.13M	86.13M
Shares Outstanding (Diluted)	94.36M	94.75M	94.71M	82.16M	82.48M	82.48M	81.85M	81.63M	1.67M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	17.75M	86.13M	86.13M	86.13M
EPS (Basic)	-0.98	-0.18	-0.38	-0.98	-0.52	-0.56	-0.43	-0.47	-24.19	-23.19	0.75	0.75	-1.73	-0.82	-0.43	-0.43	0.00	-0.02	-0.02	-0.02
EPS (Diluted)	-0.98	-0.18	-0.38	-0.98	-0.52	-0.56	-0.43	-0.47	-24.16	-23.22	0.67	0.68	-1.73	-0.82	-0.43	-0.43	0.00	-0.02	-0.02	-0.02
EBITDA	-111.69M	-23.84M	-49.06M	-54.57M	-44.29M	-48.27M	-38.99M	-38.62M	-30.43M	-28.63M	26.83M	26.83M	-10.85M	-9.94M	-4.98M	-4.98M	-104.33K	-1.35M	-1.35M	-1.35M
EBIT	-111.74M	-23.87M	-51.4M	-54.59M	-51M	-48.28M	-39M	-38.63M	-30.43M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	119.88K	-1.35M	-1.35M	-1.35M
Depreciation & Amortization	51K	28K	17.74K	13.9K	5.17K	6.16K	11.91K	8.3K	2.25K	7.54K	18K	18K	1.4K	1K	1K	1K	250.00	250.00	250.00	250.00